Here, we show that SEMA3C is a secreted soluble autocrine growth factor that drives growth and treatment resistance of prostate cancer via activation of multiple RTKs such as EGFR, MET, and ErbB2 in a cognate ligand‐independent manner. The gene discussed is MET; the disease is prostate carcinoma.